Milestone Pharmaceuticals Inc. (MIST)

NMS – Real vaqt narxi. Valyuta: USD

1.24

-0.01 (-0.80%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

1.25

+0.01 (0.81%)

Bozordan keyin: Jun 26, 2026, 7:59 PM EDT

10.06.2026

Milestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks Transcript

09.06.2026

Milestone Pharmaceuticals: Here Comes The Revenue Ramp

Milestone Pharmaceuticals Inc. remains a Strong Buy, despite recent volatility and a 37% stock decline since FDA approval of Cardamyst. Cardamyst's rapid-acting efficacy, expanding insurance coverage, and unique market position underpin a compelling medium-term ramp in prescriptions and revenue. International expansion and a Phase 3 trial for AFib-RVR could significantly enlarge MIST's addressable market and long-term growth prospects.

14.05.2026

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ to take place on Tuesday, May 19, 2026 in New York.

13.05.2026

Milestone Pharmaceuticals Q1 Earnings Call Highlights

Milestone Pharmaceuticals NASDAQ: MIST said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal supraventricular tachycardia, or PSVT, while the company also moved ahead with a Phase 3 program in atrial fibrillation with rapid ventricular rate.

13.05.2026

Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript

13.05.2026

Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) reported first-quarter earnings on Wednesday before the market opened. Here's a rundown of the report.

13.05.2026

Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates

Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of $0.06. This compares to a loss of $0.31 per share a year ago.

Videolar

No Data

There is no data to display

Press-relizlar

13.05.2026

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

MONTREAL and CHARLOTTE, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced financial results for the first quarter ending March 31, 2026, and provided corporate and regulatory updates.

10.04.2026

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT

Registry Study Design Presented at the Preventive Cardiovascular Nurses Association 2026 Cardiovascular Nursing Symposium Registry Study Design Presented at the Preventive Cardiovascular Nurses Association 2026 Cardiovascular Nursing Symposium

02.04.2026

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., April 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 123,000 options (the “Options”) to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the “Plan”), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to the hiring of three new employees.

31.03.2026

Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

MONTREAL and CHARLOTTE, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Express Scripts, one of the nation's largest pharmacy benefit managers, has added CARDAMYST™ (etripamil) nasal spray to its commercial national formularies, effective March 27, 2026.

Milestone Pharmaceuticals Inc. (MIST)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Milestone Pharmaceuticals Inc. (MIST)

Milestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks Transcript

Milestone Pharmaceuticals: Here Comes The Revenue Ramp

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Milestone Pharmaceuticals Q1 Earnings Call Highlights

Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript

Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales

Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates

Videolar

No Data

Press-relizlar

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

Milestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks Transcript

Milestone Pharmaceuticals: Here Comes The Revenue Ramp

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Milestone Pharmaceuticals Q1 Earnings Call Highlights

Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript

Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales

Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates

Videolar

No Data

Press-relizlar

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

Search stocks

Milestone Pharmaceuticals Inc. (MIST)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Milestone Pharmaceuticals Inc. (MIST)

Milestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks Transcript

Milestone Pharmaceuticals: Here Comes The Revenue Ramp

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Milestone Pharmaceuticals Q1 Earnings Call Highlights

Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript

Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales

Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates

Videolar

No Data

Press-relizlar

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

Milestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks Transcript

Milestone Pharmaceuticals: Here Comes The Revenue Ramp

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Milestone Pharmaceuticals Q1 Earnings Call Highlights

Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript

Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales

Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates

Videolar

No Data

Press-relizlar

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies